Clinical trial · Interventional
Virtual Reality for Chemotherapy Patients
Virtual Reality as a Symptom Control Intervention for Women With Gynecologic Cancer Receiving Chemotherapy: A Pilot Proof of Concept Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor enrollment and researcher left the institution
Summary
Brief summary (as posted)
The purpose of this feasibility prospective study is to explore if the use of virtual reality as a distraction intervention for women with gynecologic cancer during chemotherapy administration reduces adverse symptoms. In this study, the treatment participants serve as their own control. The study will be performed over a 3 month period limit in order to assess implementation capability and symptom management of gynecologic cancer patients receiving chemotherapy treatment at Columbia University Irving Medical Center (CUIMC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oncologic Complications | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Destek V4 Virtual Reality Headset | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Virtual reality arm
- description
- Participants will be asked to use virtual reality during their infusion for a duration of at least 10 minutes.
- interventionNames
- Other: Destek V4 Virtual Reality Headset
Primary outcomes (2)
- measure
- Symptom Survey A
- timeFrame
- upto 3 months
- description
- Symptom Survey A will be administered prior to first three chemotherapy infusions. Descriptive statistics will be utilized to characterize the survey question response proportions (i.e., distribution of responses to questions on the survey) (frequency, percent). Estimated differences in survey responses between 1) patient's perception pre-intervention vs. 2) patient's perception post-intervention, will be evaluated by the two-sample t-test, Wilcoxon rank-sum test, chi-square test, and Fisher's exact test, as appropriate. All analyses will be performed in SAS version 9.3
- measure
- Symptom Survey B
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. All gynecologic oncology patients undergoing intravenous (IV) chemotherapy as standard of care treatment for their disease. 2. Age greater than or equal to 18 years 3. Patients willing to participate on surveys prior to and post chemotherapy infusion treatments 4. Patient must own or have access to an iphone or android device with virtual reality application capability Exclusion Criteria: 1. Patients with hearing impairment 2. Patients with known balance disorders such as vertigo/cybersickness 3. Patients with known history of epileptic seizures 4. Patients who are unable to wear the virtual reality headset 5. Patients who are not receiving pre-chemotherapy labs as part of their standard treatment protocol 6. Patients who receive additional intravenous medications, such as antihypertensives, steroids, analgesics, anxiolytics during chemotherapy session that is not part of the standard chemotherapy regimen.
References
Publications (0)
Data not yet available